- Home
- SDST vs PBYI Comparison
SDST vs PBYI Comparison
Compare SDST & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDST
- PBYI
- Stock Information
- Founded
- SDST 2022
- PBYI 2010
- Country
- SDST United States
- PBYI United States
- Employees
- SDST N/A
- PBYI N/A
- Industry
- SDST Blank Checks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SDST Finance
- PBYI Health Care
- Exchange
- SDST Nasdaq
- PBYI Nasdaq
- Market Cap
- SDST 176.9M
- PBYI 145.3M
- IPO Year
- SDST N/A
- PBYI N/A
- Fundamental
- Price
- SDST $0.76
- PBYI $2.91
- Analyst Decision
- SDST Strong Buy
- PBYI Strong Buy
- Analyst Count
- SDST 1
- PBYI 1
- Target Price
- SDST $13.00
- PBYI $7.00
- AVG Volume (30 Days)
- SDST 2.0M
- PBYI 289.1K
- Earning Date
- SDST 03-04-2025
- PBYI 02-27-2025
- Dividend Yield
- SDST N/A
- PBYI N/A
- EPS Growth
- SDST N/A
- PBYI 492.79
- EPS
- SDST N/A
- PBYI 0.47
- Revenue
- SDST N/A
- PBYI $243,569,000.00
- Revenue This Year
- SDST N/A
- PBYI N/A
- Revenue Next Year
- SDST N/A
- PBYI N/A
- P/E Ratio
- SDST N/A
- PBYI $6.24
- Revenue Growth
- SDST N/A
- PBYI 6.30
- 52 Week Low
- SDST $0.66
- PBYI $2.23
- 52 Week High
- SDST $28.38
- PBYI $7.15
- Technical
- Relative Strength Index (RSI)
- SDST N/A
- PBYI 48.76
- Support Level
- SDST N/A
- PBYI $2.69
- Resistance Level
- SDST N/A
- PBYI $2.98
- Average True Range (ATR)
- SDST 0.00
- PBYI 0.12
- MACD
- SDST 0.00
- PBYI 0.01
- Stochastic Oscillator
- SDST 0.00
- PBYI 58.11
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is a development stage manufacturer of battery-grade lithium products deigned to supply the EV industry and helping to secure America's leadership in the energy transition. They enjoy a diversified supply of lithium from American brine sources.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.